Intervention not reported
Primary outcome 2: participant‐ or parent‐rated participant quality of life score at the end of active treatment Scales used: DLQI, IDQoL, Skindex‐29, CDLQI. On those scales, the higher the score, the more severely the quality of life is affected ... · male and female patients 0 to 55 years of age with physician‐diagnosed eczema
1 finding from 1 review
Intervention not reported
Primary outcome 2: participant‐ or parent‐rated family quality of life score at the end of active treatment Scale used: DFI, FDLQI. On those scales, the higher the score, the more severely the quality of life is affected Duration of · male and female patients 0 to 55 years of age with physician‐diagnosed eczema
1 finding from 1 review
Intervention not reported
Secondary outcome 4: global eczema severity score (total SCORAD) at the end of active treatment (Investigator‐rated eczema severity) Scale used: total SCORAD ranging from 0 to 103. The higher the score, the more severe the disease Duration of · male and female patients 0 to 55 years of age with physician‐diagnosed eczema
1 finding from 1 review
Intervention not reported
Secondary outcome 6: adverse events (gastrointestinal symptoms) during active treatment Duration of · male and female patients 0 to 55 years of age with physician‐diagnosed eczema
The intervention showed no clear difference in secondary outcome 6: adverse events (gastrointestinal symptoms)… (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality ( · people with hepatic encephalopathy
The intervention showed no clear difference in all‐cause mortality ( (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events ‐ Change of/or withdrawal from treatment ( · people with hepatic encephalopathy
It is very uncertain whether the intervention changes adverse events ‐ Change of/or withdrawal from treatment ( (very low certainty).
1 finding from 1 review
Intervention not reported
Quality of life ( · people with hepatic encephalopathy
1 finding from 1 review
Intervention not reported
Plasma ammonia concentration (final and change scores) (μmol/L) ( · people with hepatic encephalopathy
1 finding from 1 review
Intervention not reported
No‐recovery (incomplete resolution of clinical symptoms) ( · people with hepatic encephalopathy
The intervention probably leads to lower no‐recovery (incomplete resolution of clinical symptoms) ( (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events ‐ Overt hepatic encephalopathy ( · people with hepatic encephalopathy
The intervention may leads to lower adverse events ‐ Overt hepatic encephalopathy ( (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events ‐ Change of/or withdrawal from treatment ( · people with hepatic encephalopathy
It is very uncertain whether the intervention changes adverse events ‐ Change of/or withdrawal from treatment ( (very low certainty).
1 finding from 1 review
Intervention not reported
Quality of life ( · people with hepatic encephalopathy
1 finding from 1 review
Intervention not reported
Plasma ammonia concentration (final and change scores) (μmol/L) ( · people with hepatic encephalopathy
1 finding from 1 review
Intervention not reported
All‐cause mortality ( · people with hepatic encephalopathy
It is very uncertain whether the intervention changes all‐cause mortality ( (very low certainty).
1 finding from 1 review
Intervention not reported
No‐recovery (incomplete resolution of clinical symptoms) ( · people with hepatic encephalopathy
It is very uncertain whether the intervention changes no‐recovery (incomplete resolution of clinical symptoms) ( (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events ‐ Overt hepatic encephalopathy ( · people with hepatic encephalopathy
It is very uncertain whether the intervention changes adverse events ‐ Overt hepatic encephalopathy ( (very low certainty).
1 finding from 1 review
Number of participants with symptomatic UTI · people with neuropathic bladder
It is very uncertain whether intravesical bacterial interference changes symptomatic UTI compared with placebo (very low certainty).
1 finding from 1 review
Duration of diarrhoea · children with persistent diarrhoea
1 finding from 1 review
Stool frequency on day 5 · children with persistent diarrhoea
1 finding from 1 review
Length of hospital stay · children with persistent diarrhoea
1 finding from 1 review